This week, the state of Illinois released a draft Medicaid 1115 waiver that included additional treatment benefits for addiction treatment such as extended-release injectable naltrexone, short-term residential treatment in an institution for mental disease, substance use disorder case management, withdrawal management, and recovery coaching (see Illinois’ Behavioral Health Transformation Section 1115 Demonstration Waiver). While this is only a draft waiver, and we’ll have to wait for details about Illinois’ plans, this is one piece of a broader trend. Illinois is joining a host of states – California, Maryland, Massachusetts, and Virginia – that have expanded their Medicaid addiction treatment . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
If you are already a member, log in to your account to access this resource and more.

You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Addiction Treatment Services

Addiction is a chronic disease, which causes individuals to seek “reward” from substance-use or other activities whether or not they may cause harm. Addiction treatment has been in the spotlight as payers, policymakers, and health systems struggle to address the opioid crisis and increasing substance-related mortality rates. As a result, the addiction treatment market is shifting—there is expanded coverage for residential treatment, a push towards greater integration and care coordination, and new competitors entering the market—creating new challenges and opportunities for organizations working in addiction treatment.


Latest Resources
See All
Researchers from the Veterans Affairs St. Louis Health Care System found that veterans with type 2 diabetes who were prescribed glucagon-like peptide-1 receptor agonists (GLP-1s) had a lower risk of developing substance use disorders (SUDs) compared to those prescribed sodium-glucose cotransporter-2 (SGLT-2) inhibitors, according to a study published in The BMJ. The study was conducted to examine whether GLP-1 medications—originally developed to treat type 2 diabetes and increasingly used for weight management—are associated with differences… Read